Benchmark Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a 'Buy' rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a $50 price target.
October 20, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst has reiterated a 'Buy' rating on Halozyme Therapeutics and maintained a $50 price target.
The reiteration of a 'Buy' rating by a Benchmark analyst and the maintenance of a $50 price target indicates a positive outlook for Halozyme Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100